Wais, V <br/><br/>
Reduced-toxicity conditioning for allogeneic hematopoietic cell transplantation in elderly or comorbid patients with AML using fludarabine, BCNU and melphalan: disease stage at transplant determines outcome.  [electronic resource] 

 -  Bone marrow transplantation  01 2018 
 - 94-96 p.  digital 
<br/><br/> Publication Type: Letter; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1476-5365 
<br/><br/><label>Standard No.: </label>10.1038/bmt.2017.211  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--pharmacology<br/>Carmustine--pharmacology<br/>Comorbidity<br/>Female<br/>Hematopoietic Stem Cell Transplantation--methods<br/>Humans<br/>Leukemia, Myeloid, Acute--drug therapy<br/>Male<br/>Melphalan--pharmacology<br/>Neoplasm Staging<br/>Transplantation Conditioning--methods<br/>Transplantation, Homologous--methods<br/>Vidarabine--analogs & derivatives